Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Rezetecan in HER2-Expressing Advanced Solid Tumors
NCT07631884Phase 2Not yet recruiting
- Sponsor
- Haihua Yuan
- Start
- Jun 2026
- Primary completion
- Dec 2028
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab rezetecan in solid tumor, sponsored by Haihua Yuan. Primary endpoint: Objective Response Rate up to 24 months. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07631884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07631884.